Should I buy or sell Akero Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks .

What is Akero Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1-year price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $33.00 to $43.00. On average, they anticipate the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts .

How have AKRO shares performed in 2024?

Akero Therapeutics' stock was trading at $23.35 at the beginning of the year. Since then, AKRO stock has decreased by 10.6% and is now trading at $20.88. View the best growth stocks for 2024 here .

Are investors shorting Akero Therapeutics?

Akero Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 7,840,000 shares, a decline of 17.2% from the March 15th total of 9,470,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 5.8 days. View Akero Therapeutics' Short Interest .

When is Akero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our AKRO earnings forecast .

How were Akero Therapeutics' earnings last quarter?

Akero Therapeutics, Inc. (NASDAQ:AKRO) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.17.

What ETFs hold Akero Therapeutics' stock?

ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Invesco DWA SmallCap Momentum ETF (DWAS) and ALPS Medical Breakthroughs ETF (SBIO) . Simplify Health Care ETF (PINK) .

What other stocks do shareholders of Akero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC) , Kaleido Biosciences (KLDO) , Sorrento Therapeutics (SRNE) , Editas Medicine (EDIT) , Gossamer Bio (GOSS) , Provention Bio (PRVB) , Alector (ALEC) , Micron Technology (MU) , VIVUS (VVUS) .

When did Akero Therapeutics IPO?

Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Akero Therapeutics' major shareholders?

Akero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Quattro Financial Advisors LLC (0.02%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andrew Cheng , Catriona Yale , G Walmsley Graham, Jonathan Young , Kevin Bitterman , Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White . View institutional ownership trends .

How do I buy shares of Akero Therapeutics?

Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:AKRO

Akero Therapeutics (AKRO) Stock Price, News & Analysis

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Free AKRO Stock Alerts

$20.67

+0.16 (+0.78%)

(As of 10:39 AM ET)

Compare

Today's Range: $20.39
▼
$20.93
50-Day Range: $19.76
▼
$31.18
52-Week Range: $11.25
▼
$58.38

Volume: 97,245 shs
Average Volume: 1.27 million shs
Market Capitalization: $1.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.00

Get Akero Therapeutics alerts:

Akero Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 86.8% Upside
$39.00 Price Target
Short Interest: Healthy
11.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.75
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$3.32 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.06) to ($4.49) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

209th out of 918 stocks

Pharmaceutical Preparations Industry

83rd out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Akero Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
11.34% of the outstanding shares of Akero Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akero Therapeutics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Akero Therapeutics has recently decreased by 17.21%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Akero Therapeutics does not currently pay a dividend.
Dividend Growth
Akero Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Akero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Akero Therapeutics is -0.75.

2.7

News and Social Media Coverage

News Sentiment
Akero Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Akero Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,319,877.00 in company stock.
Percentage Held by Insiders
Only 9.69% of the stock of Akero Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($4.06) to ($4.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akero Therapeutics is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akero Therapeutics is -7.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akero Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradingTips

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

Get your FREE look at these THREE companies right here.

About Akero Therapeutics Stock (NASDAQ:AKRO)

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

AKRO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKRO Stock News Headlines

April 4, 2024 | insidertrades.com

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 5,000 Shares

April 7, 2024 | stockhouse.com

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

April 3, 2024 | stockhouse.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

April 3, 2024 | seekingalpha.com

Akero Therapeutics' EFX Data Warrants Caution

April 2, 2024 | prnewswire.com

Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.

March 28, 2024 | msn.com

4D Molecular slips after regulatory update on lead asset

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 18, 2024 | finance.yahoo.com

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

March 17, 2024 | investing.com

Akero Therapeutics CSO sells shares worth over $17k

March 17, 2024 | investing.com

Akero Therapeutics CFO sells shares to cover tax withholding

March 16, 2024 | finance.yahoo.com

AKRO Apr 2024 42.500 call

March 16, 2024 | msn.com

Madrigal’s stock surges as FDA approves first drug for liver disease MASH

March 15, 2024 | msn.com

Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades

March 10, 2024 | finance.yahoo.com

AKRO Aug 2024 30.000 put

March 9, 2024 | finance.yahoo.com

AKRO Aug 2024 17.500 put

March 8, 2024 | globenewswire.com

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

March 8, 2024 | markets.businessinsider.com

Akero Therapeutics’ Strong Trial Results and Market Positioning Justify Buy Rating

March 8, 2024 | finance.yahoo.com

AKRO Jan 2025 2.500 call

March 7, 2024 | globenewswire.com

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

March 7, 2024 | finance.yahoo.com

President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)

March 6, 2024 | msn.com

Akero's fatty liver disease drug lessens scarring in mid-stage trial

March 6, 2024 | msn.com

Akero Therapeutics announces pricing of stock offering to raise $319M

March 5, 2024 | globenewswire.com

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

March 5, 2024 | markets.businessinsider.com

Akero Therapeutics Commences Public Offering Of $300 Mln Of Shares

March 4, 2024 | realmoney.thestreet.com

Akero Therapeutics price target raised by $14 at Evercore ISI, here's why

See More Headlines

Receive AKRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AKRO
CUSIP: N/A
CIK: 1744659
Web: www.akerotx.com
Phone: (650) 487-6488
Fax: N/A
Employees: 55
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.00
High Stock Price Target: $43.00
Low Stock Price Target: $33.00
Potential Upside/Downside: +90.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-151,760,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.59%
Return on Assets: -27.10%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 29.27
Quick Ratio: 29.27

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.61 per share
Price / Book: 2.13

Miscellaneous

Outstanding Shares: 56,300,000
Free Float: 50,843,000
Market Cap: $1.15 billion
Optionable: Optionable
Beta: -0.38

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Andrew Cheng M.D. (Age 57)
Ph.D., President, CEO & Director
Comp: $1.22M
Dr. Jonathan M. Young J.D. (Age 54)
Ph.D., Co-Founder, Executive VP, COO & Secretary
Comp: $763.3k
Dr. Timothy Rolph (Age 70)
Co-Founder & Chief Scientific Officer
Comp: $819.4k
Mr. William R. White J.D. (Age 50)
Executive VP, CFO, Treasurer & Head of Corporate Development
Comp: $768.4k
Ms. Catriona Yale (Age 52)
Executive VP & Chief Development Officer
Comp: $754.8k
Mr. Patrick Lamy (Age 51)
Senior Vice President of Commercial Strategy
Mr. John J. Schembri (Age 62)
VP of Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKRO Stock Analysis - Frequently Asked Questions

Should I buy or sell Akero Therapeutics stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKRO shares.
View AKRO analyst ratings or view top-rated stocks.
What is Akero Therapeutics' stock price target for 2024?: 6 Wall Street research analysts have issued 1-year price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $33.00 to $43.00. On average, they anticipate the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price.
View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts.
How have AKRO shares performed in 2024?: Akero Therapeutics' stock was trading at $23.35 at the beginning of the year. Since then, AKRO stock has decreased by 10.6% and is now trading at $20.88.
View the best growth stocks for 2024 here.
Are investors shorting Akero Therapeutics?: Akero Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 7,840,000 shares, a decline of 17.2% from the March 15th total of 9,470,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 5.8 days.
View Akero Therapeutics' Short Interest.
When is Akero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our AKRO earnings forecast.
How were Akero Therapeutics' earnings last quarter?: Akero Therapeutics, Inc. (NASDAQ:AKRO) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.17.

What ETFs hold Akero Therapeutics' stock?: ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco DWA SmallCap Momentum ETF (DWAS) and ALPS Medical Breakthroughs ETF (SBIO).Simplify Health Care ETF (PINK).
What other stocks do shareholders of Akero Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS).
When did Akero Therapeutics IPO?: Akero Therapeutics (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager.
Who are Akero Therapeutics' major shareholders?: Akero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Quattro Financial Advisors LLC (0.02%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White.
View institutional ownership trends.
How do I buy shares of Akero Therapeutics?: Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKRO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial